A medical device go-to-market strategy is not a software go-to-market strategy with a longer sales cycle. It is a fundamentally different discipline, governed by constraints that do not exist in most B2B categories: a device cannot be sold until a regulator clears it, cannot generate real revenue until a payer agrees to reimburse it, cannot be adopted until clinicians trust the evidence behind it, and cannot enter a hospital until a value-analysis committee approves it. Any one of these gates can stall a launch for a year. Miss the sequencing between them and you can burn your entire runway waiting.
The companies that launch medical devices successfully treat these gates as a critical path to be planned in parallel, not a sequence to be discovered one surprise at a time. Regulatory, reimbursement, and clinical evidence strategy must be developed together, years before the commercial launch, because they depend on and inform one another. The clinical trial that earns FDA clearance is often the same evidence base that convinces payers to reimburse and KOLs to advocate -- if you design it that way from the start.
This guide walks through the five gates of a medical device go-to-market strategy -- the industry-specific counterpart to our general go-to-market strategy guide -- in the order they constrain your commercial timeline: regulatory, reimbursement, clinical evidence and KOLs, hospital procurement, and the specialized sales model that ties them together. This is the kind of multi-year, multi-stakeholder orchestration where a fractional Head of GTM with device experience is worth far more than a generalist, and where the broader medtech industry hub can point you to leaders who have navigated it before.
Gate 1: Regulatory Pathway (FDA Clearance or Approval)
Nothing about your commercial strategy is real until you know your regulatory pathway, because the pathway determines your timeline, your evidence burden, and your cost.
Know your pathway early. The three common FDA routes differ enormously:
- 510(k) clearance -- for devices "substantially equivalent" to an existing predicate. Faster (often 3-6 months of review) and cheaper, but requires an appropriate predicate device.
- De Novo -- for novel low-to-moderate-risk devices with no predicate. Establishes a new classification.
- Premarket Approval (PMA) -- for high-risk (Class III) devices. The most rigorous path, typically requiring pivotal clinical trials and often multiple years.
The pathway dictates everything downstream. A 510(k) product can plan a commercial launch far sooner than a PMA product that needs a pivotal trial. Your GTM timeline must be built backward from realistic clearance dates, with buffer for FDA questions and Additional Information requests, which are the norm, not the exception.
Build the regulatory and commercial teams in the same room. The regulatory submission defines your indications for use -- the specific patient population and clinical claims you are legally allowed to market. If regulatory writes a narrow indication and marketing has been building demand for a broader use, you have an off-label problem the day you launch. Align the intended claims with the commercial strategy before the submission, not after clearance.
Gate 2: Reimbursement and Payer Strategy
Here is the truth that surprises first-time device founders: FDA clearance lets you sell the device, but reimbursement determines whether anyone can afford to buy it. A cleared device with no reimbursement path is a science project, because hospitals and physicians will not adopt something they cannot get paid for.
Reimbursement has three interlocking components, often called coverage, coding, and payment:
- Coding: does an existing CPT or HCPCS code cover the procedure your device enables, or do you need a new one? New codes can take years to establish through the AMA and CMS processes.
- Coverage: will Medicare and commercial payers agree the procedure is medically necessary for a given population? This depends heavily on clinical evidence.
- Payment: what dollar amount is attached to the code, and does it cover the provider's cost of using your device profitably?
Start reimbursement strategy during clinical development, not after clearance. The clinical trial that earns FDA clearance should be designed to also generate the health-economic and outcomes data that payers demand -- cost savings, reduced readmissions, improved outcomes. Retrofitting that evidence after the fact means running expensive additional studies and delaying revenue by years.
Model the economic buyer's math. A hospital adopts your device only if the reimbursement it receives, minus the device cost, leaves it whole or better. Build the pro forma from the provider's perspective. If your device improves outcomes but destroys the hospital's margin on the procedure, adoption stalls regardless of clinical merit.
Gate 3: Clinical Evidence and KOL Engagement
Medical devices are adopted on the basis of clinical trust, and clinical trust is built through evidence and the physicians who vouch for it. This gate runs in parallel with the first two and feeds both.
Design the evidence strategy for three audiences at once. Your clinical data has to satisfy the FDA (safety and effectiveness), payers (medical necessity and economic value), and clinicians (real-world outcomes and ease of use). The most efficient device companies design a clinical program that produces evidence for all three from overlapping studies, rather than running separate trials for each stakeholder.
Engage key opinion leaders (KOLs) years before launch. KOLs -- the respected physicians whose adoption and publications move a specialty -- are the single most powerful adoption lever in medtech. Involve them early:
- Advisory input during device design and trial design, so the study answers questions the field actually cares about.
- Principal investigators on your pivotal and post-market studies, lending credibility to the data.
- Podium and publication presence -- KOLs presenting your data at major medical conferences and publishing in peer-reviewed journals creates the evidence base peers require.
- Peer-to-peer education at launch, training the early-adopter surgeons or clinicians who follow the KOLs' lead.
A device with strong data but no KOL advocacy adopts slowly; a device with credible KOLs championing it at the major society meetings adopts fast. This is why KOL relationships are a multi-year investment, not a launch-week campaign.
Gate 4: Hospital Procurement and GPO Cycles
Even with clearance, reimbursement, and clinical champions, your device still has to clear the hospital's own gauntlet -- and hospital purchasing is one of the slowest, most committee-driven buying processes in all of B2B.
Understand the value-analysis committee (VAC). Most hospitals route new device purchases through a value-analysis committee -- a cross-functional group of clinicians, supply-chain staff, and finance leaders who evaluate clinical benefit, economic impact, and safety before approving a new product. Your clinical champion gets you onto the VAC agenda; your health-economic evidence gets you through it. Prepare a VAC dossier: clinical evidence, economic model, reimbursement confirmation, and comparison to current practice.
Navigate GPOs and IDNs. Many hospitals buy through group purchasing organizations (GPOs) that negotiate contracts on behalf of members, and increasingly through integrated delivery networks (IDNs) that centralize purchasing across many facilities. Getting on a GPO contract can be a gate in itself -- without it, individual hospitals may be contractually discouraged from buying. Map which GPOs and IDNs your target accounts belong to and build those contracting relationships as a distinct workstream.
Plan for long, committee-driven cycles. A hospital adoption cycle commonly runs 6-18 months from first clinical interest to purchase order. Your commercial forecast and cash planning must assume this. First-time device companies routinely model software-like sales cycles and run out of money waiting for procurement realities to catch up.
Gate 5: The Specialized Sales Model
Medical device sales is a distinct discipline because the product is often used, not just bought -- and the rep is frequently in the room when it is.
Clinical selling, not feature selling. Device reps sell to physicians by demonstrating clinical value and, in many categories, by providing case support -- being present during procedures to ensure correct use. This demands reps with clinical fluency, not generic B2B closers. Hiring and training this team is a longer, costlier process than staffing a SaaS sales floor.
Multi-stakeholder deal navigation. A single device sale can require winning the physician (who wants it), the value-analysis committee (who vets it), supply chain (who contracts it), and finance (who funds it) -- each with different priorities. Your reps and clinical specialists must multi-thread across all of them, armed with the right evidence for each audience.
Case support and training as part of GTM. Adoption does not end at the purchase order. Many devices require in-service training and ongoing procedural support to drive utilization -- and utilization, not the initial sale, is where recurring revenue lives. Build the clinical support model into the go-to-market plan and its cost structure from the start.
Sequencing the Gates
The defining skill in medical device go-to-market is parallel sequencing. Regulatory, reimbursement, and clinical evidence strategy must be developed together, starting years before commercial launch, because each informs the others: the pivotal trial earns clearance, generates payer evidence, and creates KOL advocacy all at once when designed with intent. Hospital procurement and the specialized sales model then convert that groundwork into adoption -- slowly, through committees and clinical trust.
The companies that stumble are the ones that treat these as discrete phases discovered in sequence -- getting FDA clearance, then wondering about reimbursement, then realizing they need clinical champions, then meeting the value-analysis committee for the first time. Each late discovery costs a year and a chunk of runway.
If you are bringing a device to market, map all five gates before you finalize your clinical trial design, because that trial is the fulcrum that either serves every downstream stakeholder or forces you to run additional studies later. This is dense, high-stakes orchestration, and it is exactly where a fractional Head of GTM who has run medtech launches -- and the specialized leaders profiled across the medtech industry hub -- can keep your timeline and your runway intact.